Article Text

Download PDFPDF
Cost of epimacular brachytherapy for treatment-naive neovascular age-related macular degeneration
  1. Timothy L Jackson1,2,
  2. Lucy Kirkpatrick2,
  3. Genevieve Tang3,
  4. Somdutt Prasad4
  1. 1School of Medicine, King's College London, London, UK
  2. 2Department of Ophthalmology, King's College Hospital, London, UK
  3. 3Quorum Consulting, San Francisco, California, USA
  4. 4Department of Ophthalmology, Arrowe Park Hospital, Wirral, UK
  1. Correspondence to Tim Jackson, Department of Ophthalmology, King's College Hospital, London SE5 9RS, UK; t.jackson1{at}

Statistics from

Dear Sir,

Epimacular brachytherapy (EMB) combines pars plana vitrectomy and intraocular delivery of 24 grey irradiation for the treatment of neovascular age-related macular degeneration. We previously compared the projected cost of treatment with EMB, in combination with as required (Pro Re Nata (PRN)) anti-vascular endothelial growth factor (VEGF) therapy, with PRN anti-VEGF monotherapy.1 At that time, phase III trials of EMB were unavailable, and our projections were based on phase II trials.2 ,3 The CABERNET study recently provided phase III data in treatment-naive disease.4 Herein we present updated costs for …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.